29 results on '"Versteeg, Leroy"'
Search Results
2. Heterologous mRNA-protein vaccination with Tc24 induces a robust cellular immune response against Trypanosoma cruzi, characterized by an increased level of polyfunctional CD8+ T-cells
- Author
-
Poveda, Cristina, Leão, Ana Carolina, Mancino, Chiara, Taraballi, Francesca, Chen, Yi-Lin, Adhikari, Rakesh, Villar, Maria Jose, Kundu, Rakhi, Nguyen, Duc M., Versteeg, Leroy, Strych, Ulrich, Hotez, Peter J., Bottazzi, Maria Elena, Pollet, Jeroen, and Jones, Kathryn M.
- Published
- 2023
- Full Text
- View/download PDF
3. DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 M pro inhibitors
- Author
-
Chamakuri, Srinivas, Lu, Shuo, Ucisik, Melek Nihan, Bohren, Kurt M., Chen, Ying-Chu, Du, Huang-Chi, Faver, John C., Jimmidi, Ravikumar, Li, Feng, Li, Jian-Yuan, Nyshadham, Pranavanand, Palmer, Stephen S., Pollet, Jeroen, Qin, Xuan, Ronca, Shannon E., Sankaran, Banumathi, Sharma, Kiran L., Tan, Zhi, Versteeg, Leroy, Yu, Zhifeng, Matzuk, Martin M., Palzkill, Timothy, and Young, Damian W.
- Published
- 2021
4. Vaccine-linked chemotherapy induces IL-17 production and reduces cardiac pathology during acute Trypanosoma cruzi infection
- Author
-
Cruz-Chan, Julio V., Villanueva-Lizama, Liliana E., Versteeg, Leroy, Damania, Ashish, Villar, Maria José, González-López, Cristina, Keegan, Brian, Pollet, Jeroen, Gusovsky, Fabian, Hotez, Peter J., Bottazzi, Maria Elena, and Jones, Kathryn M.
- Published
- 2021
- Full Text
- View/download PDF
5. Choice of adjuvant and antigen composition alters the immunogenic profile of a SARS-CoV-2 subunit vaccine.
- Author
-
Lykins, William R., Pollet, Jeroen, White, Jessica A., Keegan, Brian, Versteeg, Leroy, Strych, Ulrich, Wen-Hsiang Chen, Mohamath, Raodoh, Ramer-Denisoff, Gabi, Reed, Sierra, Beaver, Samuel, Gerhardt, Alana, Voigt, Emily A., Tomai, Mark A., Sitrin, Robert, Choy, Robert K. M., Cassels, Frederick J., Hotez, Peter J., Bottazzi, Maria Elena, and Fox, Christopher B.
- Published
- 2024
- Full Text
- View/download PDF
6. A simple fluorescence-based assay for quantification of the Toll-Like Receptor agonist E6020 in vaccine formulations
- Author
-
Pollet, Jeroen, Versteeg, Leroy, Rezende, Wanderson, Strych, Ulrich, Gusovsky, Fabian, Hotez, Peter J., and Bottazzi, Maria Elena
- Published
- 2017
- Full Text
- View/download PDF
7. A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2.
- Author
-
Thimmiraju, Syamala Rani, Adhikari, Rakesh, Villar, Maria Jose, Lee, Jungsoon, Liu, Zhuyun, Kundu, Rakhi, Chen, Yi-Lin, Sharma, Suman, Ghei, Karm, Keegan, Brian, Versteeg, Leroy, Gillespie, Portia M., Ciciriello, Allan, Islam, Nelufa Y., Poveda, Cristina, Uzcategui, Nestor, Chen, Wen-Hsiang, Kimata, Jason T., Zhan, Bin, and Strych, Ulrich
- Subjects
SARS-CoV-2 Omicron variant ,ANTIBODY titer ,SARS-CoV-2 Delta variant ,RECOMBINANT proteins ,SARS-CoV-2 - Abstract
(1) Background: We previously reported the development of a recombinant protein SARS-CoV-2 vaccine, consisting of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, adjuvanted with aluminum hydroxide (alum) and CpG oligonucleotides. In mice and non-human primates, our wild-type (WT) RBD vaccine induced high neutralizing antibody titers against the WT isolate of the virus, and, with partners in India and Indonesia, it was later developed into two closely resembling human vaccines, Corbevax and Indovac. Here, we describe the development and characterization of a next-generation vaccine adapted to the recently emerging XBB variants of SARS-CoV-2. (2) Methods: We conducted preclinical studies in mice using a novel yeast-produced SARS-CoV-2 XBB.1.5 RBD subunit vaccine candidate formulated with alum and CpG. We examined the neutralization profile of sera obtained from mice vaccinated twice intramuscularly at a 21-day interval with the XBB.1.5-based RBD vaccine, against WT, Beta, Delta, BA.4, BQ.1.1, BA.2.75.2, XBB.1.16, XBB.1.5, and EG.5.1 SARS-CoV-2 pseudoviruses. (3) Results: The XBB.1.5 RBD/CpG/alum vaccine elicited a robust antibody response in mice. Furthermore, the serum from vaccinated mice demonstrated potent neutralization against the XBB.1.5 pseudovirus as well as several other Omicron pseudoviruses. However, regardless of the high antibody cross-reactivity with ELISA, the anti-XBB.1.5 RBD antigen serum showed low neutralizing titers against the WT and Delta virus variants. (4) Conclusions: Whereas we observed modest cross-neutralization against Omicron subvariants with the sera from mice vaccinated with the WT RBD/CpG/Alum vaccine or with the BA.4/5-based vaccine, the sera raised against the XBB.1.5 RBD showed robust cross-neutralization. These findings underscore the imminent opportunity for an updated vaccine formulation utilizing the XBB.1.5 RBD antigen. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Vaccine-linked chemotherapy improves cardiac structure and function in a mouse model of chronic Chagas disease.
- Author
-
Jones, Kathryn M., Mangin, Elise N., Reynolds, Corey L., Villanueva, Liliana E., Vladimir Cruz, Julio, Versteeg, Leroy, Keegan, Brian, Kendricks, April, Pollet, Jeroen, Gusovsky, Fabian, Bottazzi, Maria Elena, and Hotez, Peter J.
- Subjects
CHAGAS' disease ,CARDIAC pacing ,LABORATORY mice ,ANIMAL disease models ,CHRONIC diseases ,SYMPTOMS ,ARRHYTHMIA ,ANGIOTENSIN II - Abstract
Introduction: Chagas disease, caused by chronic infection with the protozoan parasite Trypanosoma cruzi, affects 6-7 million people worldwide. The major clinical manifestation of Chagas disease is chronic Chagasic cardiomyopathy (CCC), which encompasses a spectrum of symptoms including arrhythmias, hypertrophy, dilated cardiomyopathy, heart failure, and sudden death. Current treatment is limited to two antiparasitic drugs, benznidazole (BNZ) and nifurtimox, but both have limited efficacy to halt the progression of CCC. We developed a vaccine-linked chemotherapy strategy using our vaccine consisting of recombinant Tc24-C4 protein and a TLR-4 agonist adjuvant in a stable squalene emulsion, in combination with low dose benznidazole treatment. We previously demonstrated in acute infection models that this strategy parasite specific immune responses, and reduced parasite burdens and cardiac pathology. Here, we tested our vaccine-linked chemotherapy strategy in a mouse model of chronic T. cruzi infection to evaluate the effect on cardiac function. Methods: Female BALB/c mice infected with 500 blood form T. cruzi H1 strain trypomastigotes were treated beginning 70 days after infection with a low dose of BNZ and either low or high dose of vaccine, in both sequential and concurrent treatments streams. Control mice were untreated, or administered only one treatment. Cardiac health was monitored throughout the course of treatment by echocardiography and electrocardiograms. Approximately 8 months after infection, endpoint histopathology was performed to measure cardiac fibrosis and cellular infiltration. Results: Vaccine-linked chemotherapy improved cardiac function as evidenced by amelioration of altered left ventricular wall thickness, left ventricular diameter, as well as ejection fraction and fractional shortening by approximately 4 months of infection, corresponding to two months after treatment was initiated. At study endpoint, vaccine-linked chemotherapy reduced cardiac cellular infiltration, and induced significantly increased antigen specific IFN-γ and IL-10 release from splenocytes, as well as a trend toward increased IL-17A. Discussion: These data suggest that vaccine-linked chemotherapy ameliorates changes in cardiac structure and function induced by infection with T. cruzi. Importantly, similar to our acute model, the vaccine-linked chemotherapy strategy induced durable antigen specific immune responses, suggesting the potential for a long lasting protective effect. Future studies will evaluate additional treatments that can further improve cardiac function during chronic infection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access.
- Author
-
Hotez, Peter J., Adhikari, Rakesh, Chen, Wen-Hsiang, Chen, Yi-Lin, Gillespie, Portia, Islam, Nelufa Y., Keegan, Brian, Tyagi Kundu, Rakhi, Lee, Jungsoon, Liu, Zhuyun, Kimata, Jason T., Oezguen, Numan, Pollet, Jeroen, Poveda, Cristina, Razavi, Kay, Ronca, Shannon E., Strych, Ulrich, Thimmiraju, Syamala R., Versteeg, Leroy, and Villar-Mondragon, Maria Jose
- Subjects
COVID-19 vaccines ,VACCINATION ,EMERGING infectious diseases ,RECOMBINANT proteins ,GENE expression - Abstract
The development of a yeast-expressed recombinant protein-based vaccine technology co-developed with LMIC vaccine producers and suitable as a COVID-19 vaccine for global access is described. The proof-of-concept for developing a SARS-CoV-2 spike protein receptor-binding domain (RBD) antigen as a yeast-derived recombinant protein vaccine technology is described. Genetic Engineering: The strategy is presented for the design and genetic modification used during cloning and expression in the yeast system. Process and Assay Development: A summary is presented of how a scalable, reproducible, and robust production process for the recombinant protein COVID-19 vaccine antigen was developed. Formulation and Pre-clinical Strategy: We report on the pre-clinical and formulation strategy used for the proof-of-concept evaluation of the SARS-CoV-2 RBD vaccine antigen. Technology Transfer and Partnerships: The process used for the technology transfer and co-development with LMIC vaccine producers is described. Clinical Development and Delivery: The approach used by LMIC developers to establish the industrial process, clinical development, and deployment is described. Highlighted is an alternative model for developing new vaccines for emerging infectious diseases of pandemic importance starting with an academic institution directly transferring their technology to LMIC vaccine producers without the involvement of multinational pharma companies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine.
- Author
-
Jones, Kathryn M., Poveda, Cristina, Versteeg, Leroy, Bottazzi, Maria Elena, and Hotez, Peter J.
- Subjects
CHAGAS' disease ,COMBINED modality therapy ,PROTOZOAN diseases ,GLOBAL burden of disease ,TRYPANOSOMA cruzi - Abstract
Chronic infection with the protozoal parasite Trypanosoma cruzi leads to a progressive cardiac disease, known as chronic Chagasic cardiomyopathy (CCC). A new therapeutic Chagas disease vaccine is in development to augment the existing antiparasitic chemotherapy drugs. We report on our current understanding of the underlying immunologic and physiologic mechanisms that lead to CCC, including parasite immune escape mechanisms that allow persistence and the subsequent inflammatory and fibrotic processes that lead to clinical disease. We report on vaccine design and the observed immunotherapeutic effects including induction of a balanced T
H 1/TH 2/TH 17 immune response that leads to reduced parasite burdens and tissue pathology. Furthermore, we report vaccine-linked chemotherapy, a dose-sparing strategy to further reduce parasite burdens and tissue pathology. Our vaccine-linked chemotherapeutic approach is a multimodal treatment strategy, addressing both the parasite persistence and the underlying deleterious host inflammatory and fibrotic responses that lead to cardiac dysfunction. In targeting treatment towards patients with chronic indeterminate or early determinate Chagas disease, this vaccine-linked chemotherapeutic approach will be highly economical and will reduce the global disease burden and deaths due to CCC. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
11. DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 Mpro inhibitors.
- Author
-
Chamakuri, Srinivas, Shuo Lu, Ucisik, Melek Nihan, Bohren, Kurt M., Ying-Chu Chen, Huang-Chi Du, Faver, John C., Jimmidi, Ravikumar, Feng Li, Jian-Yuan Li, Nyshadham, Pranavanand, Palmer, Stephen S., Pollet, Jeroen, Xuan Qin, Ronca, Shannon E., Sankaran, Banumathi, Sharma, Kiran L., Zhi Tan, Versteeg, Leroy, and Zhifeng Yu
- Subjects
SARS-CoV-2 ,CHEMICAL yield ,COVID-19 pandemic ,VIRUS diseases ,CHEMICAL libraries - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has killed more than 4 million humans globally, but there is no bona fide Food and Drug Administration-approved drug-like molecule to impede the COVID-19 pandemic. The sluggish pace of traditional therapeutic discovery is poorly suited to producing targeted treatments against rapidly evolving viruses. Here, we used an affinity-based screen of 4 billion DNA-encoded molecules en masse to identify a potent class of virus-specific inhibitors of the SARS-CoV-2 main protease (M
pro ) without extensive and time-consuming medicinal chemistry. CDD-1714, the initial three-building-block screening hit (molecular weight [MW] = 542.5 g/mol), was a potent inhibitor (inhibition constant [Ki ] = 20 nM). CDD-1713, a smaller two-building-block analog (MW = 353.3 g/mol) of CDD-1714, is a reversible covalent inhibitor of Mpro (Ki = 45 nM) that binds in the protease pocket, has specificity over human proteases, and shows in vitro efficacy in a SARS-CoV-2 infectivity model. Subsequently, key regions of CDD-1713 that were necessary for inhibitory activity were identified and a potent (Ki = 37 nM), smaller (MW = 323.4 g/mol), and metabolically more stable analog (CDD-1976) was generated. Thus, screening of DNA-encoded chemical libraries can accelerate the discovery of efficacious drug-like inhibitors of emerging viral disease targets. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
12. Location and expression kinetics of Tc24 in different life stages of Trypanosoma cruzi.
- Author
-
Versteeg, Leroy, Adhikari, Rakesh, Poveda, Cristina, Villar-Mondragon, Maria Jose, Jones, Kathryn M., Hotez, Peter J., Bottazzi, Maria Elena, Tijhaar, Edwin, and Pollet, Jeroen
- Subjects
- *
TRYPANOSOMA cruzi , *ANIMAL models of inflammation , *CALCIUM-binding proteins , *CHAGAS' disease , *MONOCLONAL antibodies - Abstract
Tc24-C4, a modified recombinant flagellar calcium-binding protein of Trypanosoma cruzi, is under development as a therapeutic subunit vaccine candidate to prevent or delay progression of chronic Chagasic cardiomyopathy. When combined with Toll-like receptor agonists, Tc24-C4 immunization reduces parasitemia, parasites in cardiac tissue, and cardiac fibrosis and inflammation in animal models. To support further research on the vaccine candidate and its mechanism of action, murine monoclonal antibodies (mAbs) against Tc24-C4 were generated. Here, we report new findings made with mAb Tc24-C4/884 that detects Tc24-WT and Tc24-C4, as well as native Tc24 in T. cruzi on ELISA, western blots, and different imaging techniques. Surprisingly, detection of Tc24 by Tc24-C/884 in fixed T. cruzi trypomastigotes required permeabilization of the parasite, revealing that Tc24 is not exposed on the surface of T. cruzi, making a direct role of antibodies in the induced protection after Tc24-C4 immunization less likely. We further observed that after immunostaining T. cruzi–infected cells with mAb Tc24-C4/884, the expression of Tc24 decreases significantly when T. cruzi trypomastigotes enter host cells and transform into amastigotes. However, Tc24 is then upregulated in association with parasite flagellar growth linked to re-transformation into the trypomastigote form, prior to host cellular escape. These observations are discussed in the context of potential mechanisms of vaccine immunity. Author summary: Chagas disease is a chronic infection with Trypanosoma cruzi (T. cruzi) that affects approximately 8 million people worldwide and may cause chronic heart inflammation. The vaccine candidate Tc24-C4 is a recombinant version of the Tc24 protein, which is a flagellar calcium-binding protein expressed by T. cruzi. While animal challenge studies have shown that targeting Tc24 is very promising, it is not fully understood how Tc24 is presented to the immune system. Here, we were able to localize Tc24 in flagellated T. cruzi parasites using a novel Tc24-specific monoclonal antibody. The results showed that Tc24 is not exposed on the outside of the parasite, which suggests that antibodies against Tc24 could not bind parasites during the infection. Then, by analyzing Tc24 expression in T. cruzi—infected host cells over time, we observed that Tc24 expression is reduced after the parasite enters the cells but is restored when parasites escape the host cell again. Our study provides more insights on the location and presence of Tc24 in T. cruzi during infection in the host, and we discuss our current understanding on the mechanisms of how the Tc24 vaccine may work. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice.
- Author
-
Pollet, Jeroen, Chen, Wen-Hsiang, Versteeg, Leroy, Keegan, Brian, Zhan, Bin, Wei, Junfei, Liu, Zhuyun, Lee, Jungsoon, Kundu, Rahki, Adhikari, Rakesh, Poveda, Cristina, Villar, Maria Jose, de Araujo Leao, Ana Carolina, Altieri Rivera, Joanne, Momin, Zoha, Gillespie, Portia M., Kimata, Jason T., Strych, Ulrich, Hotez, Peter J., and Bottazzi, Maria Elena
- Published
- 2021
- Full Text
- View/download PDF
14. TLR4 agonist protects against Trypanosoma cruzi acute lethal infection by decreasing cardiac parasite burdens.
- Author
-
Villanueva‐Lizama, Liliana E., Cruz‐Chan, Julio V., Versteeg, Leroy, Teh‐Poot, Christian F., Hoffman, Kristyn, Kendricks, April, Keegan, Brian, Pollet, Jeroen, Gusovsky, Fabian, Hotez, Peter J., Bottazzi, Maria Elena, and Jones, Kathryn M.
- Subjects
TRYPANOSOMA cruzi ,PARASITE antigens ,PARASITES ,HEART fibrosis ,IMMUNE response ,INFECTION - Abstract
E6020 is a synthetic agonist of Toll‐like receptor‐4 (TLR4). The purpose of this study was to evaluate the effect of different doses of E6020‐SE on Trypanosoma cruzi‐specific immune responses and its ability to confer protection against acute lethal infection in mice. Forty female BALB/c were infected with 500 trypomastigotes of T cruzi H1 strain, divided into four groups (n = 10) and treated at 7‐ and 14‐day post‐infection (dpi) with different doses of E6020‐SE or PBS (control). Survival was followed for 51 days, mice were euthanized and hearts were collected to evaluate parasite burden, inflammation and fibrosis. We found significantly higher survival and lower parasite burdens in mice injected with E6020‐SE at all doses compared to the control group. However, E6020‐SE treatment did not significantly reduce cardiac inflammation or fibrosis. On the other hand, E6020‐SE modulated Th1 and Th2 cytokines, decreasing IFN‐γ and IL‐4 in a dose‐dependent manner after stimulation with parasite antigens. We conclude that E6020‐SE alone increased survival by decreasing cardiac parasite burdens in BALB/c mice acutely infected with T cruzi but failed to prevent cardiac damage. Our results suggest that for optimal protection, a vaccine antigen is necessary to balance and orient a protective immune response. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Protective immunity elicited by the nematode-conserved As37 recombinant protein against Ascaris suum infection.
- Author
-
Versteeg, Leroy, Wei, Junfei, Liu, Zhuyun, Keegan, Brian, Fujiwara, Ricardo T., Jones, Kathryn M., Asojo, Oluwatoyin, Strych, Ulrich, Bottazzi, Maria Elena, Hotez, Peter J., and Zhan, Bin
- Subjects
- *
ASCARIS suum , *RECOMBINANT proteins , *IMMUNE serums , *ASCARIS lumbricoides , *IMMUNITY - Abstract
Background: Ascaris lumbricoides is one of the three major soil-transmitted gastrointestinal helminths (STHs) that infect more than 440 million people in the world, ranking this neglected tropical disease among the most common afflictions of people living in poverty. Children infected with this roundworm suffer from malnutrition, growth stunting as well as cognitive and intellectual deficits. An effective vaccine is urgently needed to complement anthelmintic deworming as a better approach to control helminth infections. As37 is an immunodominant antigen of Ascaris suum, a pig roundworm closely related to the human A. lumbricoides parasite, recognized by protective immune sera from A. suum infected mice. In this study, the immunogenicity and vaccine efficacy of recombinant As37 were evaluated in a mouse model. Methodology/Principal findings: As37 was cloned and expressed as a soluble recombinant protein (rAs37) in Escherichia coli. The expressed rAs37 was highly recognized by protective immune sera from A. suum egg-infected mice. Balb/c mice immunized with 25 μg rAs37 formulated with AddaVax™ adjuvant showed significant larval worm reduction after challenge with A. suum infective eggs when compared with a PBS (49.7%) or adjuvant control (48.7%). Protection was associated with mixed Th1/2-type immune responses characterized by high titers of serological IgG1 and IgG2a and stimulation of the production of cytokines IL-4, IL-5, IL-10 and IL-13. In this experiment, the AddaVax™ adjuvant induced better protection than the Th1-type adjuvant MPLA (38.9%) and the Th2-type adjuvant Alhydrogel (40.7%). Sequence analysis revealed that As37 is a member of the immunoglobulin superfamily (IgSF) and highly conserved in other human STHs. Anti-As37 antibodies strongly recognized homologs in hookworms (Necator americanus, Ancylostoma ceylanicum, A. caninum) and in the whipworm Trichuris muris, but there was no cross-reaction with human spleen tissue extracts. These results suggest that the nematode-conserved As37 could serve as a pan-helminth vaccine antigen to prevent all STH infections without cross-reaction with human IgSF molecules. Conclusions/Significance: As37 is an A. suum expressed immunodominant antigen that elicited significant protective immunity in mice when formulated with AddaVax™. As37 is highly conserved in other STHs, but not in humans, suggesting it could be further developed as a pan-helminth vaccine against STH co-infections. Author summary: Ascaris infection is the most common infection of humans living in poverty worldwide and can result in malnutrition and stunted physical and mental development in children. A preventive vaccine is urgently needed as a complementary approach to anthelmintic deworming to increase the efficiency of STH infection control. To develop a vaccine against Ascaris infection, an immunodominant antigen, As37 of A. suum, was cloned and expressed as a soluble recombinant protein in E. coli. The recombinant As37 protein (rAs37) was highly recognized by protective immune sera from A. suum infected mice. Balb/c mice immunized with 25 μg rAs37 formulated with the adjuvant AddaVax™ showed significant larval worm reduction against challenge with A. suum infective eggs when compared to a PBS (49.7%) or adjuvant control (48.7%). Protection was associated with a mixed Th1/2-type immune response characterized by high titers of serological IgG1 and IgG2a and stimulation of the production of cytokines IL-4, IL-5, IL-10 and IL-13. The AddaVax™ adjuvant induced better protection than the Th1-type adjuvant MPLA (38.9%) and the Th2-type adjuvant Alhydrogel (40.7%). Sequence analysis revealed that As37 was a member of the immunoglobulin superfamily (IgSF) and highly conserved in other human STHs. Anti-As37 antibodies strongly recognized homologs in hookworms (Necator americanus, A. ceylanicum, A. caninum) and in the whipworm T. muris, but there was no cross-reaction with human spleen tissue extracts. These results indicate that the nematode-conserved As37 protein could be developed as a pan-helminth vaccine antigen to prevent all STH infections without reacting with human IgSF molecules. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection.
- Author
-
Barry, Meagan A., Versteeg, Leroy, Wang, Qian, Pollet, Jeroen, Zhan, Bin, Gusovsky, Fabian, Bottazzi, Maria Elena, Hotez, Peter J., and Jones, Kathryn M.
- Subjects
- *
HEART fibrosis , *TRYPANOSOMA cruzi , *CARDIOMYOPATHIES , *ACUTE phase proteins , *THERAPEUTICS , *DRUG side effects , *HEART failure - Abstract
Chagas disease, caused by the parasite Trypanosoma cruzi, develops into chronic Chagas’ cardiomyopathy in ~30% of infected individuals, characterized by conduction disorders, arrhythmias, heart failure, and even sudden cardiac death. Current anti-parasitic treatments are plagued by significant side effects and poor efficacy in the chronic phase of disease; thus, there is a pressing need for new treatment options. A therapeutic vaccine could bolster the protective TH1-mediated immune response, thereby slowing or halting the progression of chronic Chagas’ cardiomyopathy. Prior work in mice has demonstrated therapeutic efficacy of a Tc24 recombinant protein vaccine in the acute phase of Chagas disease. However, it is anticipated that humans will be vaccinated therapeutically when in the chronic phase of disease. This study investigates the therapeutic efficacy of a vaccine prototype containing recombinant protein Tc24, formulated with an emulsion containing the Toll-like receptor 4 agonist E6020 as an immunomodulatory adjuvant in a mouse model of chronic T. cruzi infection. Among outbred ICR mice vaccinated during chronic T. cruzi infection, there is a significant increase in the number of animals with undetectable systemic parasitemia (60% of vaccinated mice compared to 0% in the sham vaccine control group), and a two-fold reduction in cardiac fibrosis over the control group. The vaccinated mice produce a robust protective TH1-biased immune response to the vaccine, as demonstrated by a significant increase in antigen-specific IFNγ-production, the number of antigen-specific IFNγ-producing cells, and IgG2a antibody titers. Importantly, therapeutic vaccination significantly reduced cardiac fibrosis in chronically infected mice. This is a first study demonstrating therapeutic efficacy of the prototype Tc24 recombinant protein and E6020 stable emulsion vaccine against cardiac fibrosis in a mouse model of chronic T. cruzi infection. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Trichuris muris whey acidic protein induces type 2 protective immunity against whipworm.
- Author
-
Briggs, Neima, Wei, Junfei, Versteeg, Leroy, Zhan, Bin, Keegan, Brian, Damania, Ashish, Pollet, Jeroen, Hayes, Kelly S., Beaumier, Coreen, Seid, Christopher A., Leong, Jamie, Grencis, Richard K., Bottazzi, Maria Elena, Sastry, K. Jagannadha, and Hotez, Peter J.
- Subjects
WHIPWORMS ,TRICHURIASIS ,IMMUNE response ,INFLAMMATORY bowel diseases ,VACCINATION - Abstract
Human whipworm (Trichuris trichiura) infects approximately 1 in 15 people worldwide, representing the leading infectious cause of colitis and subsequent, inflammatory bowel disease (IBD). Current control measures focused on mass deworming have had limited success due to low drug efficacies. Vaccination would be an ideal, cost-effective strategy to induce protective immunity, leading to control of infection and transmission. Here we report the identification of whey acidic protein, a whipworm secretory protein, as a strong immunogen for inducing protective efficacy in a surrogate mouse T. muris infection model. The recombinant WAP protein (rTm-WAP49), as well as a single, highly conserved repeat within WAP (fragment 8) expressed as an Na-GST-1 fusion protein (rTm-WAP-F8+Na-GST-1), generate a strong T helper type 2 (Th2) immune response when delivered as subcutaneous vaccines formulated with Montanide ISA 720. Oral challenge with T. muris infective eggs following vaccination led to a significant reduction in worm burden of 48% by rTm-WAP49 and 33% by rTm-WAP-F8+Na-GST-1. The cellular immune correlates of protection included significant antigen-specific production of Th2 cytokines IL-4, IL-9, and IL-13 by cells isolated from the vaccine-draining inguinal lymph nodes, parasite-draining mesenteric lymph nodes, and spleen in mice vaccinated with either rTm-WAP49 or rTm-WAP-F8+Na-GST-1. The humoral immune correlates included a high antigen-specific ratio of IgG1 to IgG2a, without eliciting an IgE-mediated allergic response. Immunofluorescent staining of adult T. muris with WAP antisera identified the worm’s pathogenic stichosome organ as the site of secretion of native Tm-WAP protein into the colonic mucosa. Given the high sequence conservation for the WAP proteins from T. muris and T. trichiura, the results presented here support the WAP protein to be further evaluated as a potential human whipworm vaccine candidate. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
18. Yeast-expressed recombinant As16 protects mice against Ascaris suum infection through induction of a Th2-skewed immune response.
- Author
-
Wei, Junfei, Versteeg, Leroy, Liu, Zhuyun, Keegan, Brian, Gazzinelli-Guimarães, Ana Clara, Fujiwara, Ricardo T., Briggs, Neima, Jones, Kathryn M., Strych, Ulrich, Beaumier, Coreen M., Bottazzi, Maria Elena, Hotez, Peter J., and Zhan, Bin
- Subjects
- *
ASCARIS suum , *HELMINTHIASIS , *IMMUNE response , *T helper cells , *CHOLERA toxin , *LABORATORY mice , *IMMUNOLOGY - Abstract
Background: Ascariasis remains the most common helminth infection in humans. As an alternative or complementary approach to global deworming, a pan-anthelminthic vaccine is under development targeting Ascaris, hookworm, and Trichuris infections. As16 and As14 have previously been described as two genetically related proteins from Ascaris suum that induced protective immunity in mice when formulated with cholera toxin B subunit (CTB) as an adjuvant, but the exact protective mechanism was not well understood. Methodology/Principal findings: As16 and As14 were highly expressed as soluble recombinant proteins (rAs16 and rAs14) in Pichia pastoris. The yeast-expressed rAs16 was highly recognized by immune sera from mice infected with A. suum eggs and elicited 99.6% protection against A. suum re-infection. Mice immunized with rAs16 formulated with ISA720 displayed significant larva reduction (36.7%) and stunted larval development against A. suum eggs challenge. The protective immunity was associated with a predominant Th2-type response characterized by high titers of serological IgG1 (IgG1/IgG2a > 2000) and high levels of IL-4 and IL-5 produced by restimulated splenocytes. A similar level of protection was observed in mice immunized with rAs16 formulated with alum (Alhydrogel), known to induce mainly a Th2-type immune response, whereas mice immunized with rAs16 formulated with MPLA or AddaVax, both known to induce a Th1-type biased response, were not significantly protected against A. suum infection. The rAs14 protein was not recognized by A. suum infected mouse sera and mice immunized with rAs14 formulated with ISA720 did not show significant protection against challenge infection, possibly due to the protein’s inaccessibility to the host immune system or a Th1-type response was induced which would counter a protective Th2-type response. Conclusions/Significance: Yeast-expressed rAs16 formulated with ISA720 or alum induced significant protection in mice against A. suum egg challenge that associates with a Th2-skewed immune response, suggesting that rAS16 could be a feasible vaccine candidate against ascariasis. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
19. Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease.
- Author
-
Seid, Christopher A., Jones, Kathryn M., Pollet, Jeroen, Keegan, Brian, Hudspeth, Elissa, Hammond, Molly, Wei, Junfei, McAtee, C. Patrick, Versteeg, Leroy, Gutierrez, Amanda, Liu, Zhuyun, Zhan, Bin, Respress, Jonathan L., Strych, Ulrich, Bottazzi, Maria Elena, and Hotez, Peter J.
- Published
- 2017
- Full Text
- View/download PDF
20. Transferring Luminex® cytokine assays to a wall-less plate technology: Validation and comparison study with plasma and cell culture supernatants.
- Author
-
Versteeg, Leroy, Le Guezennec, Xavier, Zhan, Bin, Liu, Zhuyun, Angagaw, Minilik, Woodhouse, Janice D., Biswas, Subhabrata, and Beaumier, Coreen M.
- Subjects
- *
CYTOKINES , *CELL culture , *PLASMA cells , *ENCEPHALOMYELITIS , *COST effectiveness - Abstract
Luminex® technology provides a powerful methodology for multiplex cytokine detection but remains constrained by high costs and a minimum of 25–50 μL sample volume requirement per assay-well often hindering analysis of limited biological samples. Here we compare the results of Luminex-based cytokine multiplexing assay performed using conventional 96-well microtiter plates and a particular 96-well wall-less plate based on Droparray® technology (“DA-Bead”). The application of the DA-Bead plate allows 80% reduction of sample and reagent volume, thus an opportunity for significant cost savings in Luminex reagents with no change to the workflow. To compare the DA-Bead method to the conventional method, two different types of samples were tested with two different commercially available Luminex kits and the results for each method were compared. The first type was splenocyte culture supernatants from murine spleens which were harvested from mice immunized with Ascaris suum protein As 24 and followed by cell stimulation ex vivo at various time points with this same antigen. Cytokine levels in these supernatants were evaluated using a Bio-Plex® T H 1/T H 2 8-plex kit. The second sample type was plasma from mice from an experimental autoimmune encephalomyelitis (EAE) study, and these samples were evaluated using a Milliplex® T H 17 25-plex kit. The data showed that the DA-Bead method for analysis was comparable to, if not superior to, the conventional method in terms of consistency/precision, accuracy, sensitivity and dynamic range and these results are not specific to sample type, reagents, or commercial vendor. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
21. The Role of Cellular Immune Responses on Chikungunya Virus Infection-Induced Arthritis.
- Author
-
Versteeg, Leroy, Febres, Maria, and Beaumier, Coreen
- Published
- 2016
- Full Text
- View/download PDF
22. Expression, purification, and characterization of the Necator americanus aspartic protease-1 ( Na -APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine.
- Author
-
Seid, Christopher A, Curti, Elena, Jones, R Mark, Hudspeth, Elissa, Rezende, Wanderson, Pollet, Jeroen, Center, Lori, Versteeg, Leroy, Pritchard, Sonya, Musiychuk, Konstantin, Yusibov, Vidadi, Hotez, Peter J, and Bottazzi, Maria Elena
- Published
- 2015
- Full Text
- View/download PDF
23. Invited Commentary on Genetically Modified Mosquitoes for Population Control of Pathogen-Transmitting Wild-Type Mosquitoes.
- Author
-
Versteeg, Leroy, Wang, Qian, and Beaumier, Coreen
- Published
- 2016
- Full Text
- View/download PDF
24. Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections.
- Author
-
Versteeg, Leroy, Almutairi, Mashal M., Hotez, Peter J., and Pollet, Jeroen
- Subjects
PARASITIC diseases ,PARASITE life cycles ,VACCINES ,MESSENGER RNA ,MIDDLE-income countries - Abstract
Despite medical progress, more than a billion people still suffer daily from parasitic infections. Vaccination is recognized as one of the most sustainable options to control parasitic diseases. However, the development of protective and therapeutic vaccines against tropical parasites has proven to be exceptionally challenging for both scientific and economic reasons. For certain parasitic diseases, traditional vaccine platforms are not well-suited, due to the complexity of the parasite life cycles and the parasite's ability to evade the human immune system. An effective anti-parasite vaccine platform needs to have the ability to develop and test novel candidate antigens fast and at high-throughput; it further needs to allow for multivalent combinations and must evoke a strong and well-defined immune response. Anti-parasitic vaccines need to be safe and economically attractive, especially in the world's low- and middle-income countries. This review evaluates the potential of in vitro transcribed mRNA vaccines as a new class of preventive and therapeutic vaccine technologies for parasitic infections. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. Covalent vaccination with Trypanosoma cruzi Tc24 induces catalytic antibody production.
- Author
-
Gunter, Sarah M., Versteeg, Leroy, Jones, Kathryn M., Keegan, Brian P., Strych, Ulrich, Bottazzi, Maria Elena, Hotez, Peter J., and Brown, Eric L.
- Subjects
- *
TRYPANOSOMA cruzi , *CATALYTIC antibodies , *IMMUNOGLOBULIN M , *B cell differentiation , *FLOW cytometry , *VACCINATION - Abstract
Summary: Trypanosoma cruzi 24 (Tc24) is a recently described B‐cell superantigen (BC‐SAg) expressed by all developmental stages of T. cruzi, the causative agent of Chagas disease. BC‐SAgs are immunoevasins that interfere with the catalytic response available to a subset of natural antibodies comprising the preimmune (innate) repertoire. Electrophilic modifications of BC‐SAgs facilitate the formation of highly energetic covalent reactions favouring B‐cell differentiation instead of B‐cell downregulation. Therefore, the aim of this study was to convert the inhibitory signals delivered to B‐cells with specificity for Tc24 into activating signals after conjugating electrophilic phosphonate groups to recombinant Tc24 (eTc24). Covalent immunization with eTc24 increased the binding affinity between eTc24 and naturally nucleophilic immunoglobulins with specificity for this BC‐SAg. Flow cytometric analyses demonstrated that eTc24 but not Tc24 or other electrophilically modified control proteins bound Tc24‐specific IgM+ B‐cells covalently. In addition, immunization of mice with eTc24 adjuvanted with ISA720 induced the production of catalytic responses specific for Tc24 compared to the abrogation of this response in mice immunized with Tc24/ISA720. eTc24‐immunized mice also produced IgMs that bound recombinant Tc24 compared to the binding observed for IgMs purified from non eTc24‐immunized controls. These data suggest that eTc24 immunization overrides the immunosuppressive properties of this BC‐SAg. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. Cover Image.
- Author
-
Gunter, Sarah M., Versteeg, Leroy, Jones, Kathryn M., Keegan, Brian P., Strych, Ulrich, Bottazzi, Maria Elena, Hotez, Peter J., and Brown, Eric L.
- Subjects
- *
TRYPANOSOMA cruzi , *CATALYTIC antibodies , *VACCINATION - Abstract
The cover image is based on the Original Article Covalent vaccination with Trypanosoma cruzi Tc24 induces catalytic antibody production by Sarah M. Gunter et al., DOI: 10.1111/pim.12585. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
27. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
- Author
-
Pollet, Jeroen, Strych, Ulrich, Chen, Wen-Hsiang, Versteeg, Leroy, Keegan, Brian, Zhan, Bin, Wei, Junfei, Liu, Zhuyun, Lee, Jungsoon, Kundu, Rahki, Adhikari, Rakesh, Poveda, Cristina, Jose Villar, Maria, Rani Thimmiraju, Syamala, Lopez, Brianna, Gillespie, Portia M., Ronca, Shannon, Kimata, Jason T., Reers, Martin, and Paradkar, Vikram
- Subjects
- *
SARS-CoV-2 , *RECOMBINANT proteins , *PROTEIN domains , *CONVALESCENT plasma , *MONOCLONAL antibodies , *SARS-CoV-2 Delta variant , *IMMUNOGLOBULINS - Abstract
We conducted preclinical studies in mice using a yeast-produced SARS-CoV-2 RBD subunit vaccine candidate formulated with aluminum hydroxide (alum) and CpG deoxynucleotides. This formulation is equivalent to the CorbevaxTM vaccine that recently received emergency use authorization by the Drugs Controller General of India. We compared the immune response of mice vaccinated with RBD/alum to mice vaccinated with RBD/alum + CpG. We also evaluated mice immunized with RBD/alum + CpG and boosted with RBD/alum. Mice were immunized twice intramuscularly at a 21-day interval. Compared to two doses of the /alum formulation, the RBD/alum + CpG vaccine induced a stronger and more balanced Th1/Th2 cellular immune response, with high levels of neutralizing antibodies against the original Wuhan isolate of SARS-CoV-2 as well as the B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 and (Delta) variants. Neutralizing antibody titers against the B.1.1.529 (BA.1, Omicron) variant exceeded those in human convalescent plasma after Wuhan infection but were lower than against the other variants. Interestingly, the second dose did not benefit from the addition of CpG, possibly allowing dose-sparing of the adjuvant in the future. The data reported here reinforces that the RBD/alum + CpG vaccine formulation is suitable for inducing broadly neutralizing antibodies against SARS-CoV-2, including variants of concern. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate.
- Author
-
Chen, Wen-Hsiang, Pollet, Jeroen, Strych, Ulrich, Lee, Jungsoon, Liu, Zhuyun, Kundu, Rakhi Tyagi, Versteeg, Leroy, Villar, Maria Jose, Adhikari, Rakesh, Wei, Junfei, Poveda, Cristina, Keegan, Brian, Bailey, Aaron Oakley, Chen, Yi-Lin, Gillespie, Portia M., Kimata, Jason T., Zhan, Bin, Hotez, Peter J., and Bottazzi, Maria Elena
- Subjects
- *
COVID-19 vaccines , *SARS-CoV-2 , *RECOMBINANT proteins , *ANTIBODY titer , *VACCINE effectiveness , *PICHIA pastoris , *IMMUNOGLOBULINS - Abstract
SARS-CoV-2 protein subunit vaccines are currently being evaluated by multiple manufacturers to address the global vaccine equity gap, and need for low-cost, easy to scale, safe, and effective COVID-19 vaccines. In this paper, we report on the generation of the receptor-binding domain RBD203-N1 yeast expression construct, which produces a recombinant protein capable of eliciting a robust immune response and protection in mice against SARS-CoV-2 challenge infections. The RBD203-N1 antigen was expressed in the yeast Pichia pastoris X33. After fermentation at the 5 L scale, the protein was purified by hydrophobic interaction chromatography followed by anion exchange chromatography. The purified protein was characterized biophysically and biochemically, and after its formulation, the immunogenicity was evaluated in mice. Sera were evaluated for their efficacy using a SARS-CoV-2 pseudovirus assay. The RBD203-N1 protein was expressed with a yield of 492.9 ± 3.0 mg/L of fermentation supernatant. A two-step purification process produced a >96% pure protein with a recovery rate of 55 ± 3% (total yield of purified protein: 270.5 ± 13.2 mg/L fermentation supernatant). The protein was characterized to be a homogeneous monomer that showed a well-defined secondary structure, was thermally stable, antigenic, and when adjuvanted on Alhydrogel in the presence of CpG it was immunogenic and induced high levels of neutralizing antibodies against SARS-CoV-2 pseudovirus. The characteristics of the RBD203-N1 protein-based vaccine show that this candidate is another well suited RBD-based construct for technology transfer to manufacturing entities and feasibility of transition into the clinic to evaluate its immunogenicity and safety in humans. • The yeast construct expressing SARS-CoV-2 RBD203-N1 shows high fermentation yield and overall purification recovery. • The production process for RBD203-N1 is scalable and reproducible. • Purified RBD203-N1 has high purity and well-defined structure, and is antigenic and functional. • When formulated with alum and CpG, RBD203-N1 induces high antibody titers and neutralizing antibodies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate.
- Author
-
Chen, Wen-Hsiang, Wei, Junfei, Kundu, Rakhi Tyagi, Adhikari, Rakesh, Liu, Zhuyun, Lee, Jungsoon, Versteeg, Leroy, Poveda, Cristina, Keegan, Brian, Villar, Maria Jose, de Araujo Leao, Ana C., Rivera, Joanne Altieri, Gillespie, Portia M., Pollet, Jeroen, Strych, Ulrich, Zhan, Bin, Hotez, Peter J., and Bottazzi, Maria Elena
- Subjects
- *
COVID-19 , *COVID-19 vaccines , *SARS-CoV-2 , *CORONAVIRUSES , *ANGIOTENSIN converting enzyme , *DRUG utilization - Abstract
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has now spread worldwide to infect over 110 million people, with approximately 2.5 million reported deaths. A safe and effective vaccine remains urgently needed. We constructed three variants of the recombinant receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein (residues 331–549) in yeast as follows: (1) a "wild type" RBD (RBD219-WT), (2) a deglycosylated form (RBD219-N1) by deleting the first N-glycosylation site, and (3) a combined deglycosylated and cysteine-mutagenized form (C538A-mutated variant (RBD219-N1C1)). We compared the expression yields, biophysical characteristics, and functionality of the proteins produced from these constructs. These three recombinant RBDs showed similar secondary and tertiary structure thermal stability and had the same affinity to their receptor, angiotensin-converting enzyme 2 (ACE-2), suggesting that the selected deletion or mutations did not cause any significant structural changes or alteration of function. However, RBD219-N1C1 had a higher fermentation yield, was easier to purify, was not hyperglycosylated, and had a lower tendency to form oligomers, and thus was selected for further vaccine development and evaluation. By genetic modification, we were able to design a better-controlled and more stable vaccine candidate, which is an essential and important criterion for any process and manufacturing of biologics or drugs for human use. • Engineered yeast-expressed SARS-CoV-2 RBD, RBD219-N1C1, prevents oligomerization and improves stability. • The engineering does not impact protein structure and functionality. • The engineering improves the fermentation yield. • RBD219-N1C1 can be purified with a simple purification scheme. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.